よむ、つかう、まなぶ。
10参考資料２ 令和6年度総括報告書「同種造血幹細胞移植患者に対する優先度の高い公的予防接種の再接種に関する研究」 (17 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Oncol. 2024 May 10;42（14）:1699-1721.
42
(PNCRM7) and haemophilus influenzae
conjugate vaccines (HIB) in pediatric and adult
[PMID: 38498792]
36
Okinaka, K. et al. Clinical characteristics and
recipients of an allogeneic hematopoietic cell
risk factors of pneumococcal diseases in
transplantation (alloHCT). Biol Blood Marrow
recipients of allogeneic hematopoietic stem cell
Transplant 14, 1022-1030 (2008).
transplants in the late phase: A retrospective
https://doi.org:10.1016/j.bbmt.2008.06.012
registry study. Journal of infection and
37
39
https://doi.org:10.1016/j.jiac.2023.04.015
Recipients. Biology of blood and marrow
van Aalst, M. et al. Incidence of invasive
pneumococcal disease in immunocompromised
transplantation : journal of the American Society
for Blood and Marrow Transplantation 26,
patients: A systematic review and meta-analysis.
421-427 (2020).
Travel Med Infect Dis 24, 89-100 (2018).
https://doi.org:10.1016/j.bbmt.2019.10.006
Hematopoietic Stem Cell Transplantation
44
Meisel, R. et al. Pneumococcal conjugate
Maeda, H. et al. Long-term impact of
vaccine provides early protective antibody
pneumococcal conjugate vaccines for children
responses in children after related and unrelated
on adult pneumococcal pneumonia in Japan: Two
allogeneic hematopoietic stem cell
multicenter observational studies from 2011 to
transplantation. Blood 109, 2322-2326 (2007).
2020. Vaccine 40, 5504-5512 (2022).
https://doi.org:10.1182/blood-2006-06-03228
https://doi.org:10.1016/j.vaccine.2022.07.041
4
Garcia Quesada, M. et al. Serotype distribution
45
Cordonnier, C. et al. Randomized study of early
of remaining invasive pneumococcal disease
versus late immunization with pneumococcal
after extensive use of ten-valent and 13-valent
conjugate vaccine after allogeneic stem cell
pneumococcal conjugate vaccines (the
transplantation. Clin Infect Dis 48, 1392-1401
PSERENADE project): a global surveillance
(2009). https://doi.org:10.1086/598324
46
Cordonnier, C. et al. Immunogenicity, safety,
445-456 (2025).
and tolerability of 13-valent pneumococcal
https://doi.org:10.1016/S1473-3099(24)00588
conjugate vaccine followed by 23-valent
-7
pneumococcal polysaccharide vaccine in
Kumar, D. et al. A randomized, double-blind
recipients of allogeneic hematopoietic stem cell
trial of pneumococcal vaccination in adult
transplant aged >/=2 years: an open-label study.
allogeneic stem cell transplant donors and
Clin Infect Dis 61, 313-323 (2015).
recipients. Clinical infectious diseases : an
https://doi.org:10.1093/cid/civ287
official publication of the Infectious Diseases
Society of America 45, 1576-1582 (2007).
41
Roberts, M. B. et al. Clinical Effectiveness of
Conjugate Pneumococcal Vaccination in
analysis. The Lancet infectious diseases 25,
40
43
chemotherapy : official journal of the Japan
Society of Chemotherapy 29, 726-730 (2023).
https://doi.org:10.1016/j.tmaid.2018.05.016
38
Pao, M. et al. Response to pneumococcal
47
Wilck, M. et al. A Phase 3, Randomized,
Double-Blind, Comparator-Controlled Study to
https://doi.org:10.1086/523583
Evaluate Safety, Tolerability, and
Patel, S. R. et al. Revaccination with measles,
Immunogenicity of V114, a 15-Valent
tetanus, poliovirus, Haemophilus influenzae type
Pneumococcal Conjugate Vaccine, in Allogeneic
B, meningococcus C, and pneumococcus
Hematopoietic Cell Transplant Recipients
vaccines in children after hematopoietic stem
(PNEU-STEM). Clinical infectious diseases : an
cell transplantation. Clin Infect Dis 44, 625-634
official publication of the Infectious Diseases
(2007). https://doi.org:10.1086/511641
17
42
(PNCRM7) and haemophilus influenzae
conjugate vaccines (HIB) in pediatric and adult
[PMID: 38498792]
36
Okinaka, K. et al. Clinical characteristics and
recipients of an allogeneic hematopoietic cell
risk factors of pneumococcal diseases in
transplantation (alloHCT). Biol Blood Marrow
recipients of allogeneic hematopoietic stem cell
Transplant 14, 1022-1030 (2008).
transplants in the late phase: A retrospective
https://doi.org:10.1016/j.bbmt.2008.06.012
registry study. Journal of infection and
37
39
https://doi.org:10.1016/j.jiac.2023.04.015
Recipients. Biology of blood and marrow
van Aalst, M. et al. Incidence of invasive
pneumococcal disease in immunocompromised
transplantation : journal of the American Society
for Blood and Marrow Transplantation 26,
patients: A systematic review and meta-analysis.
421-427 (2020).
Travel Med Infect Dis 24, 89-100 (2018).
https://doi.org:10.1016/j.bbmt.2019.10.006
Hematopoietic Stem Cell Transplantation
44
Meisel, R. et al. Pneumococcal conjugate
Maeda, H. et al. Long-term impact of
vaccine provides early protective antibody
pneumococcal conjugate vaccines for children
responses in children after related and unrelated
on adult pneumococcal pneumonia in Japan: Two
allogeneic hematopoietic stem cell
multicenter observational studies from 2011 to
transplantation. Blood 109, 2322-2326 (2007).
2020. Vaccine 40, 5504-5512 (2022).
https://doi.org:10.1182/blood-2006-06-03228
https://doi.org:10.1016/j.vaccine.2022.07.041
4
Garcia Quesada, M. et al. Serotype distribution
45
Cordonnier, C. et al. Randomized study of early
of remaining invasive pneumococcal disease
versus late immunization with pneumococcal
after extensive use of ten-valent and 13-valent
conjugate vaccine after allogeneic stem cell
pneumococcal conjugate vaccines (the
transplantation. Clin Infect Dis 48, 1392-1401
PSERENADE project): a global surveillance
(2009). https://doi.org:10.1086/598324
46
Cordonnier, C. et al. Immunogenicity, safety,
445-456 (2025).
and tolerability of 13-valent pneumococcal
https://doi.org:10.1016/S1473-3099(24)00588
conjugate vaccine followed by 23-valent
-7
pneumococcal polysaccharide vaccine in
Kumar, D. et al. A randomized, double-blind
recipients of allogeneic hematopoietic stem cell
trial of pneumococcal vaccination in adult
transplant aged >/=2 years: an open-label study.
allogeneic stem cell transplant donors and
Clin Infect Dis 61, 313-323 (2015).
recipients. Clinical infectious diseases : an
https://doi.org:10.1093/cid/civ287
official publication of the Infectious Diseases
Society of America 45, 1576-1582 (2007).
41
Roberts, M. B. et al. Clinical Effectiveness of
Conjugate Pneumococcal Vaccination in
analysis. The Lancet infectious diseases 25,
40
43
chemotherapy : official journal of the Japan
Society of Chemotherapy 29, 726-730 (2023).
https://doi.org:10.1016/j.tmaid.2018.05.016
38
Pao, M. et al. Response to pneumococcal
47
Wilck, M. et al. A Phase 3, Randomized,
Double-Blind, Comparator-Controlled Study to
https://doi.org:10.1086/523583
Evaluate Safety, Tolerability, and
Patel, S. R. et al. Revaccination with measles,
Immunogenicity of V114, a 15-Valent
tetanus, poliovirus, Haemophilus influenzae type
Pneumococcal Conjugate Vaccine, in Allogeneic
B, meningococcus C, and pneumococcus
Hematopoietic Cell Transplant Recipients
vaccines in children after hematopoietic stem
(PNEU-STEM). Clinical infectious diseases : an
cell transplantation. Clin Infect Dis 44, 625-634
official publication of the Infectious Diseases
(2007). https://doi.org:10.1086/511641
17